Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $84.5833.

VERA has been the topic of several research reports. Guggenheim boosted their target price on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a report on Wednesday, July 8th. TD Cowen boosted their price objective on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group restated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Friday, July 17th.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $32.10 on Friday. The company has a fifty day moving average price of $36.91 and a 200 day moving average price of $39.63. The firm has a market cap of $2.30 billion, a PE ratio of -5.79 and a beta of 0.92. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 1-year low of $19.07 and a 1-year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) earnings per share. Research analysts predict that Vera Therapeutics will post -6.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 83,250 shares of company stock worth $3,337,770. Insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its position in Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after purchasing an additional 1,795,537 shares during the last quarter. Deerfield Management Company L.P. increased its position in shares of Vera Therapeutics by 8.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after purchasing an additional 293,040 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Vera Therapeutics by 11.9% during the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after purchasing an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Vera Therapeutics by 24.0% during the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Finally, Eversept Partners LP raised its stake in shares of Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after purchasing an additional 264,468 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.